Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes

Circulation: Cardiovascular Interventions

Volumn 2, Issue 1, 2009, Pages 35-42

  Applegate, Robert J ^a   Sacrinty, Matthew T ^a   Kutcher, Michael A ^a   Santos, Renato M ^a   Gandhi, Sanjay K ^a   Little, William C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angioplasty; Mortality; Stents

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CORONARY STENT; CORONARY STENT DIAMETER; CORONARY STENT LENGTH; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STENT THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; METALS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; THROMBOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949466469     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.108.805630     Document Type: Article

References (33)

1. de Feyter PJ, Kay P, Disco C, Serruys PW. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation. 1999;100:1777-1783.
2. Foley DP, Pieper M, Wijns W, Suryapranata H, Grollier G, Legrand V, de Scheerder I, Hanet C, Puel J, Mudra H, Bonnier HJRM, Colombo A, Thomas M, Probst P, Morice M-C, Kleijne J, Serruys PW; On behalf of the MAGIC 5L Investigators. The influence of stent length on clinical and angiographic outcome in patients undergoing elective stenting for native coronary artery lesions: final results of the magic 5L study. Eur Heart J 2001;22:1585-1593.
3. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, Di Mario C, Colombo A. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol. 1999;34:651-659.
4. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; The SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; For the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV Trial. Circulation. 2004;109:1942-1947.
6. Circulatory System Devices Advisory Panel Transcript for December 8, 2006 Meeting. Available at: http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006- 4253t2.rtf. Accessed February 2, 2007.
7. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-1061.
8. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C, For the BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48:2584-2591.
9. Brunner-La Rocca HP, Kaiser C, Pfisterer M; On behalf of the BASKET Investigators. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J. 2007;28:719-725.
10. Bertrand OF, Faurie B, Larose E, Nguyen CM, Gleeton O, Dery JP, Noel B, Proulx G, Roy L, Costerousse O, De Larochelliere R, Rodes-Cabau J. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents. J Invasiv Cardiol. 2008;20:99-104.
11. Steinberg DH, Mishra S, Javaid A, Slottow TLP, Buch AN, Roy P, Okabe T, Smith KA, Torguson R, Xue Z, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (>3.5 mm) coronary arteries. Am J Cardiol. 2007;99:599-602.
12. Quizhpe AR, Feres F, Costa JD Jr, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AMR, Sousa JEMR. Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels. Am Heart J. 2007;154:373-378.
13. Applegate RJ, Sacrinty MT, Kutcher MA, Baki TT, Gandhi SK, Santos RM, Little WC. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. Am J Cardiol. 2007;99:333-338.
14. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, Little WC. "Off-Label" stent therapy: 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607- 614.
15. Am College of Cardiology-National Cardiovascular Data Registry Module Version 3.0. 2004. Available at: http://www.accncdr.com/webNCDR/NCDRDocuments/ datadictdefsonlyv30.pdf. American College of Cardiology. 2006. Accessed May 28, 2008.
16. Mauri L, Hsieh WH, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
17. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357: 1393-1402.
18. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio V, Hall P, Popma JJ, Koglin J, Russell ME; For the TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294: 1215-1223.
19. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME; On behalf of the TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-3313.
20. Kereiakes DJ, Wang H, Popma JJ, Kuntz RE, Donohoe DJ, Schofer J, Schampaert E, Meier B, Leon MB, Moses JW. Periprocedural and late consequences of overlapping cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol. 2006;48:21-31.
21. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schomig A, Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus-or paclitaxel-eluting stents. J Am Coll Cardiol. 2006;48:1304 -1309.
22. Ellis SG, Popma JJ, Lasala JM, Koglin JJ, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Stone GW. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005;45:1193-1200.
23. Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, Resnic FS, Normand S. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation. 2008; 118:1817-1827.
24. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann F-J. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997; 30:1428-1436.
25. Hoffmann R, Mintz GS. Coronary in-stent restenosis-predictors, treatment and prevention. Eur Heart J. 2000;21:1739-1749.
26. Carrozza JP, Kuntz RE, Fishman RF, Baim DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med. 1993;118:344-349.
27. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann F-J, Fleckenstein M, Pfafferott C, Seyfarth M, Schomig A. Intra-coronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103: 2816-2821.
28. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA. 2007;297:314-316.
29. Curfman GD, Morrissey S, Jarcho JA, Drazen JM. Drug-eluting coronary stents-promise and uncertainty. N Engl J Med. 2007;356:1059-1060.
30. Farb A, Boam AB. Stent thrombosis redux-the FDA perspective. N Engl J Med. 2007;356:984-987.
31. Maisel WH. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med. 2007;356:981-984.
32. Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C; For the BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J. 2008;155:609-614.
33. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pakala R, Pinnow EE, Pichard AD, Satler LF, Kent KM, Lindsay J, Waksman R. Selective versus exclusive use of sirolimus-eluting stent implantation in multivessel coronary artery disease. Catheter Cardiovasc Interv. 2005;65:473-477.